Richard S. Houlston

2 weeks ago | nature.com | Molly Went |Charlie Mills |Amit Sud |James Allan |Richard S. Houlston

AbstractAlthough treatment options for B-cell malignancies have expanded, many patients continue to face limited response rates, highlighting an urgent need for new therapeutic targets.

Nov 6, 2024 | nature.com | Oriol Pich |Kerstin Thol |Jens Luebeck |Natasha E. Weiser |Wei-Ting Lu |Brooke E. Howitt | +11 more

AbstractExtrachromosomal DNA (ecDNA) is a major contributor to treatment resistance and poor outcome for patients with cancer1,2. Here we examine the diversity of ecDNA elements across cancer, revealing the associated tissue, genetic and mutational contexts. By analysing data from 14,778 patients with 39 tumour types from the 100,000 Genomes Project, we demonstrate that 17.1% of tumour samples contain ecDNA.

Oct 26, 2024 | nature.com | Máire Ní Leathlobhair |Anna Frangou |Ben Kinnersley |Alex J. Cornish |Eszter Lakatos |Andreas Gruber | +10 more

AbstractTesticular germ cell tumours (TGCT), which comprise seminoma and non-seminoma subtypes, are the most common cancers in young men. In this study, we present a comprehensive whole genome sequencing analysis of adult TGCTs. Leveraging samples from participants recruited via the UK National Health Service and data from the Genomics England 100,000 Genomes Project, our results provide an extended description of genomic elements underlying TGCT pathogenesis.

Oct 17, 2024 | nature.com | Molly Went |Jessica Hislop |Richard S. Houlston

Although acute myeloid leukaemia (AML) is one of the most common haematological malignancies in adults, its aetiological basis is poorly understood [1]. The only well recognised modifiable risk factors are smoking and exposure to benzene [2]. There is increasing evidence for the redox system playing a significant role in both the development and progression of AML [3].

Aug 4, 2024 | nature.com | Molly Went |Gísli H. Halldórsson |Andrea Gunnell |Philip J Law |Amit Sud |Gudmar Thorleifsson | +24 more

AbstractMultiple myeloma (MM) is an incurable malignancy of plasma cells. Epidemiological studies indicate a substantial heritable component, but the underlying mechanisms remain unclear. Here, in a genome-wide association study totaling 10,906 cases and 366,221 controls, we identify 35 MM risk loci, 12 of which are novel.